TriSalus Life Sciences®, Inc. ("TriSalus" or the "Company") , which seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care ...
Conclusion Elevated EPSTI1 expression in pSS B cells promoted TLR9 signalling activation and contributed to ... Data were processed by FlowJo Software (Tree Star, USA). Student’s t-test was used to ...
B-cell acute lymphoblastic leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most common childhood cancer, making up 35% of pediatric cancer cases, but it ...
For the 80 million people worldwide with celiac disease, the only treatment available is to cut grains like pasta and bread out of their lives. | For the 80 million people worldwide who have celiac ...
Treatment of B-cell Acute Lymphoblastic Leukaemia has improved thanks to CAR-T therapies, but relapse is still very common.
Results showed Orca’s treatment, a purified mix of donor-derived T cells and stem cells, was safer than standard transplant ...
Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety ...
Ten years of substantial work by Université de Montréal immunologist Nathalie Labrecque's team at the Montreal Clinical ...
In treating hematologic malignancies, engineered T-cell therapy outperforms standard transplantation with respect to chronic ...
Adaptimmune is rolling out its T cell therapy Tecelra for synovial sarcoma, recording $1.2 million in sales since its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback